Biostem Technologies, Inc. (NASDAQ:BSEM – Free Report) – Equities researchers at HC Wainwright lifted their Q3 2026 earnings per share estimates for shares of Biostem Technologies in a note issued to investors on Monday, August 24th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.43) for the quarter, up from their previous forecast of ($0.46). The consensus estimate for Biostem Technologies’ current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Biostem Technologies’ Q4 2026 earnings at ($0.45) EPS, FY2026 earnings at ($1.90) EPS, Q1 2027 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.31) EPS, Q3 2027 earnings at ($0.20) EPS, Q4 2027 earnings at ($0.15) EPS, FY2027 earnings at ($1.04) EPS, FY2028 earnings at ($0.09) EPS, FY2029 earnings at $0.28 EPS and FY2030 earnings at $0.58 EPS.
Separately, Weiss Ratings began coverage on shares of Biostem Technologies in a report on Wednesday, August 19th. They issued a “sell (d-)” rating on the stock. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Biostem Technologies currently has a consensus rating of “Sell”.
Biostem Technologies Stock Performance
Shares of BSEM stock opened at $3.85 on Friday. Biostem Technologies has a fifty-two week low of $2.25 and a fifty-two week high of $8.40. The stock has a 50 day moving average price of $3.59 and a two-hundred day moving average price of $4.47. The company has a market capitalization of $68.72 million, a P/E ratio of -2.40 and a beta of 0.11.
About Biostem Technologies
BioStem Technologies, Inc (NASDAQ: BSEM) is a biotechnology company focused on regenerative medicine and biologic tissue products. Through its operating businesses, the company develops, manufactures and distributes human tissue allografts intended to support wound care, surgical procedures and other regenerative applications.
Its product portfolio includes placental-tissue-based products, including amniotic membrane and related graft technologies. These products are designed for use by health-care professionals in applications such as wound management and tissue repair.
See Also
- Five stocks we like better than Biostem Technologies
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Biostem Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostem Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
